Maravai LifeSciences Holdings Inc. Class A Common Stock vs Unity Software Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Unity Software Inc trades at $40.8 (market cap $20.52B). The key difference: Unity Software Inc is far larger — about 21.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Unity Software Inc is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Unity Software Inc for 50 Days on average.
| MRVI | U | |
|---|---|---|
Market Cap | $972.90M | $20.52B |
Volume | 4,325,710 | 4,656,122 |
Sector | Health | Technology |
52-Week High | $9.00 | $49.47 |
52-Week Low | $2.83 | $17.13 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $1.08B | $20.41B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Unity Software (U) trades at $46.63, down 0.11% on the day, with strong analyst support (83% buy ratings) and a $48.01 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics, with revenue stabilizing around $1.8B and improving net margins from -66% in 2022 to -22% in 2025. Recent positive sentiment stems from Meta VR partnership news and institutional accumulation.
Unity presents a growth story with improving operational metrics but faces profitability challenges. The stock offers 3% upside to consensus targets with strong institutional backing, though persistent losses and high valuation multiples require careful risk assessment amid competitive pressures in the gaming engine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →